Dr. Reynolds lab has found that a genetic mutation in the human MPO gene causes it to be aberrantly expressed, contributing to disease.
Dr. Reynolds earned her Ph.D. at the University of California at Davis in 1980.
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS
J Clin Oncol. 2009 Oct 20;27(30):4973-9
Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.
Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, Reynolds WF
J Biol Chem. 2009 Jan 30;284(5):3158-69
Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL
Nat Med. 2007 Oct;13(10):1176-84
Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males.
Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF
J Lipid Res. 2006 Jul;47(7):1366-77
Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.
Kumar AP, Piedrafita FJ, Reynolds WF
J Biol Chem. 2004 Feb 27;279(9):8300-15
View All Publications
Primary Endoscopic Realignment of Urethral Disruption Injuries: A Double-Edged Sword?
Johnsen NV, Dmochowski RR, Mock S, Reynolds WS, Milam DF, Kaufman MR
J Urol. 2015 Apr 4;
Disparities in the Utilization of Sacral Neuromodulation Among Medicare Beneficiaries.
Laudano MA, Seklehner S, Sandhu J, Reynolds WS, Garrett KA, Milsom JW, Te AE, Kaplan SA, Chughtai B, Lee RK
J Urol. 2015 Apr 3;
Wanda Reynolds's Research Focus
Our laboratory studies the mechanisms by which oxidative damage contributes to major diseases of aging, including atherosclerosis, neurodegenerative disease, and cancer. Our main focus is myeloperoxidase (MPO), an oxidant generating enzyme that is aberrantly expressed in these disease states in humans. Our studies revealed a primate specific mutation in the human MPO promoter that leads to atypical expression, such as in astrocytes in Alzheimer’s disease, and macrophages in atherosclerosis, leading to oxidative damage and cell death. On the other hand, aberrant expression of MPO in breast cancer cells is protective, reducing incidence of recurrence following chemotherapy. We are investigating the molecular signals that lead to this atypical induction of MPO and analyzing the oxidative impact on cellular function and survival. We are also screening for small molecule antagonists of MPO that could serve as therapeutic agents.
About Wanda Reynolds
Wanda Reynolds earned her Ph.D. at the University of California at Davis in 1980. After postdoctoral training at the Scripps Research Institute, she was appointed Assistant Member in 1984, and joined the La Jolla Cancer Research Institute in 1988. She was appointed Associate Professor at the Sidney Kimmel Cancer Center in 1994, and joined the Sanford-Burnham Medical Research Institute in 2010.